Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

[Microbial Growth in Unfinished Beverages in Plastic Bottles and the Awareness of Nursing Students in a University about Microbial Contamination].

Morioka I, Uenaka A, Tanigawa A, Matsumoto Y.

Nihon Eiseigaku Zasshi. 2018;73(3):373-378. doi: 10.1265/jjh.73.373. Japanese.

2.

Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically S-Cationized Full-Length and Water-Soluble Denatured Proteins.

Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A, Fujita K, Mandai K, Atago Y, Kinoshita R, Honjo T, Matsushita H, Uenaka A, Nakayama E, Kakimi K.

Bioconjug Chem. 2015 Oct 21;26(10):2076-84. doi: 10.1021/acs.bioconjchem.5b00328. Epub 2015 Sep 22.

PMID:
26355635
3.

Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.

Miyai M, Eikawa S, Hosoi A, Iino T, Matsushita H, Isobe M, Uenaka A, Udono H, Nakajima J, Nakayama E, Kakimi K.

PLoS One. 2015 Aug 20;10(8):e0136086. doi: 10.1371/journal.pone.0136086. eCollection 2015.

4.

Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).

Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M, Nishio Y, Uenaka A, Oka M, Nakayama E.

J Thorac Oncol. 2015 Jan;10(1):74-83. doi: 10.1097/JTO.0000000000000364.

5.

Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody.

Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, Fukuda M, Uenaka A, Oka M, Nakayama E.

Clin Cancer Res. 2014 Oct 1;20(19):5052-63. doi: 10.1158/1078-0432.CCR-14-0742. Epub 2014 Aug 14.

6.

Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.

Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E.

Vaccine. 2014 Feb 12;32(8):957-64. doi: 10.1016/j.vaccine.2013.12.042. Epub 2014 Jan 5.

PMID:
24397899
7.

TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD).

Mizote Y, Wakamatsu K, Ito S, Uenaka A, Ohue Y, Kurose K, Isobe M, Ito A, Tamura Y, Honda H, Yamashita T, Nohara S, Oka M, Jimbow K, Nakayama E.

J Dermatol Sci. 2014 Mar;73(3):209-15. doi: 10.1016/j.jdermsci.2013.11.006. Epub 2013 Nov 14.

PMID:
24315204
8.

Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.

Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E.

Int J Cancer. 2013 Jan 15;132(2):345-54. doi: 10.1002/ijc.27682. Epub 2012 Jul 11.

9.

Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.

Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E.

Int J Cancer. 2012 Sep 1;131(5):E649-58. doi: 10.1002/ijc.27359. Epub 2012 Jan 3.

10.

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.

Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E.

Int J Cancer. 2011 Dec 15;129(12):2836-46. doi: 10.1002/ijc.25955. Epub 2011 Mar 29.

11.

Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.

Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, Okazaki N, Uenaka A, Nakamura Y, Fujiwara S, Mizuno N, Saika T, Ritter E, Yamasaki M, Miyata H, Ritter G, Murphy R, Venhaus R, Pan L, Old LJ, Doki Y, Nakayama E.

Int J Cancer. 2012 Feb 1;130(3):584-92. doi: 10.1002/ijc.26074. Epub 2011 May 25.

12.

Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6.

Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, Nakayama E.

J Immunol. 2010 Dec 1;185(11):6734-40. doi: 10.4049/jimmunol.1000225. Epub 2010 Nov 3.

13.

Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients.

Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E.

Vaccine. 2010 Jul 19;28(32):5338-46.

14.

Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.

Isobe M, Eikawa S, Uenaka A, Nakamura Y, Kanda T, Kohno S, Kuzushima K, Nakayama E.

Cancer Immun. 2009 Oct 1;9:8.

15.

Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity.

Nakamura Y, Noguchi Y, Satoh E, Uenaka A, Sato S, Kitazaki T, Kanda T, Soda H, Nakayama E, Kohno S.

Lung Cancer. 2009 Jul;65(1):119-22. doi: 10.1016/j.lungcan.2008.12.020. Epub 2009 Feb 4.

PMID:
19193472
16.

Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity.

Domae S, Nakamura Y, Nakamura Y, Uenaka A, Wada H, Nakata M, Oka M, Kishimoto K, Tsukamoto G, Yoshihama Y, Matsuoka J, Gochi A, Kohno S, Saika T, Sasaki A, Nakayama E, Ono T.

Int J Cancer. 2009 May 15;124(10):2347-52. doi: 10.1002/ijc.24220.

17.

Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity.

Ishida T, Obata Y, Ohara N, Matsushita H, Sato S, Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, Wada H, Yamashita T, Morishima T, Old LJ, Nakayama E.

Cancer Immun. 2008 Nov 13;8:15.

18.

Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.

Kikuchi E, Yamazaki K, Nakayama E, Sato S, Uenaka A, Yamada N, Oizumi S, Dosaka-Akita H, Nishimura M.

Cancer Immun. 2008 Aug 28;8:13.

19.

Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.

Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, Iwae S, Yonezawa K, Yamasaki M, Miyata H, Doki Y, Shiku H, Jungbluth AA, Ritter G, Murphy R, Hoffman EW, Old LJ, Monden M, Nakayama E.

Int J Cancer. 2008 Nov 15;123(10):2362-9. doi: 10.1002/ijc.23810.

20.

Identification of a CD4 T-cell epitope in tumor rejection antigen RLakt on BALB/c radiation-leukemia RL male 1.

Kaya S, Uenaka A, Sato S, Ono T, Aji T, Nakayama E.

Cancer Sci. 2008 Jul;99(7):1441-7. doi: 10.1111/j.1349-7006.2008.00843.x. Epub 2008 Apr 29.

21.

Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.

Tsuji K, Hamada T, Uenaka A, Wada H, Sato E, Isobe M, Asagoe K, Yamasaki O, Shiku H, Ritter G, Murphy R, Hoffman EW, Old LJ, Nakayama E, Iwatsuki K.

Cancer Immunol Immunother. 2008 Oct;57(10):1429-37. doi: 10.1007/s00262-008-0478-5. Epub 2008 Mar 1.

PMID:
18311489
22.

HLA-DRB1*0410-restricted recognition of XAGE-1b37-48 peptide by CD4 T cells.

Morishita Y, Uenaka A, Kaya S, Sato S, Aji T, Nakayama E.

Microbiol Immunol. 2007;51(8):755-62.

23.

T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E.

Cancer Immun. 2007 Apr 19;7:9.

24.

Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors.

Sato S, Noguchi Y, Ohara N, Uenaka A, Shimono M, Nakagawa K, Koizumi F, Ishida T, Yoshino T, Shiratori Y, Nakayama E.

Cancer Immun. 2007 Mar 5;7:5.

25.

Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells.

Shimono M, Uenaka A, Noguchi Y, Sato S, Okumura H, Nakagawa K, Kiura K, Tanimoto M, Nakayama E.

Int J Oncol. 2007 Apr;30(4):835-40.

PMID:
17332921
26.

Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.

Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A, Miyata H, Yasuda T, Doki Y, Noguchi Y, Kumon H, Tsuji K, Iwatsuki K, Shiku H, Ritter G, Murphy R, Hoffman E, Old LJ, Monden M, Nakayama E.

Int J Cancer. 2007 May 15;120(10):2178-84.

27.

OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.

Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth AA, Mhawech-Fauceglia P, Qian F, Schneider S, Sharma S, Driscoll D, Lele S, Old LJ, Nakayama E, Odunsi K.

Int J Oncol. 2006 Oct;29(4):903-10.

PMID:
16964386
28.

In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.

Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E.

Clin Cancer Res. 2006 Mar 15;12(6):1921-7.

29.

Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells.

Okumura H, Noguchi Y, Uenaka A, Aji T, Ono T, Nakagawa K, Aoe M, Shimizu N, Nakayama E.

Microbiol Immunol. 2005;49(11):1009-16.

30.

Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients.

Matsushita H, Uenaka A, Ono T, Hasegawa K, Sato S, Koizumi F, Nakagawa K, Toda M, Shingo T, Ichikawa T, Noguchi Y, Tamiya T, Furuta T, Kawase T, Date I, Nakayama E.

Cancer Sci. 2005 Nov;96(11):801-9.

31.

XAGE-1 expression in non-small cell lung cancer and antibody response in patients.

Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, Yoshino T, Yamashita K, Tsunoda T, Aoe M, Shimizu N, Nakayama E.

Clin Cancer Res. 2005 Aug 1;11(15):5496-503.

32.

[Tumor specific antigen and cytotoxic T lymphocytes].

Uenaka A, Nakayama E.

Nihon Rinsho. 2005 Apr;63 Suppl 4:568-73. Review. Japanese. No abstract available.

PMID:
15861712
33.
34.
35.
36.

ELISPOT cloning of tumor antigens recognized by cytotoxic T-lymphocytes from a cDNA expression library.

Uenaka A, Hata H, Win S, Ono T, Wada H, Nakayama E.

Cancer Immun. 2001 Jul 13;1:8.

38.

Cryptic CTL epitope on a murine sarcoma Meth A generated by exon extension as a novel mechanism.

Uenaka A, Hirano Y, Hata H, Win S, Aji T, Tanaka M, Ono T, Skipper JC, Shimizu K, Nakayama E.

J Immunol. 2003 May 1;170(9):4862-8.

39.

Immune responses against allogeneic and syngeneic tumors in aged C57BL/6 mice.

Win S, Uenaka A, Nakayama E.

Microbiol Immunol. 2002;46(7):513-9.

40.

Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.

Hata H, Uenaka A, Takada I, Kenjo A, Takahashi M, Ono T, Fujita T, Nakayama E.

Int J Oncol. 2002 May;20(5):1019-25.

PMID:
11956599
42.

Transforming activity of the RL-akt gene, a c-akt gene activated by long terminal repeat insertion in murine leukemia RL(male symbol)1 cells.

Tanino M, Matsuo M, Uenaka A, Tsukuda K, Ouchida M, Nakayama E, Shimizu K.

Mol Carcinog. 1999 Dec;26(4):286-97.

PMID:
10569805
43.

Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.

Matsuo M, Wada H, Honda S, Tawara I, Uenaka A, Kanematsu T, Nakayama E.

J Immunol. 1999 Jun 1;162(11):6420-5.

44.

Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96.

Ishii T, Udono H, Yamano T, Ohta H, Uenaka A, Ono T, Hizuta A, Tanaka N, Srivastava PK, Nakayama E.

J Immunol. 1999 Feb 1;162(3):1303-9.

46.

Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.

Takaki T, Hiraki A, Uenaka A, Gomi S, Itoh K, Udono H, Shibuya A, Tsuji T, Sekiguchi S, Nakayama E.

Int J Oncol. 1998 May;12(5):1103-9.

PMID:
9538136
47.

Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.

Manki A, Ono T, Uenaka A, Seino Y, Nakayama E.

Cancer Res. 1998 May 1;58(9):1960-4.

48.

Double-cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region.

Shimbara N, Nakajima H, Tanahashi N, Ogawa K, Niwa S, Uenaka A, Nakayama E, Tanaka K.

Genes Cells. 1997 Dec;2(12):785-800.

49.
50.

Molecular cloning and sequence analysis of the cDNA for the mouse counterpart to adult hamster liver purified growth inhibitory factor.

Hashimoto C, Masuda H, Ayaki M, Suzuki Y, Uenaka A, Seya T, Miyoshi J, Takahashi K, Inui Y.

Biochim Biophys Acta. 1997 Mar 1;1355(3):205-8.

Supplemental Content

Loading ...
Support Center